FIONA LI: Open Payments
NPI 1336175009 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,448 in 67 payments from 11 companies in 2025. Trend: 2023 $842 · 2024 $1,406 · 2025 $1,448
Food & beverage: $1,448
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $285 |
| ABBVIE INC. | 16 | $233 |
| Janssen Pharmaceuticals, Inc | 9 | $231 |
| Neurocrine BioSciences, Inc. | 11 | $163 |
| Supernus Pharmaceuticals, Inc. | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 5 | $102 |
| Alkermes, Inc. | 3 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $41 |
Products named: REXULTI, VRAYLAR, SPRAVATO, INGREZZA, Qelbree, ARISTADA, CAPLYTA, UZEDY.
Industry payments across OK — which companies pay providers there.
